POLQ overexpression has also been observed in cancers with BRCA1/BRCA2 mutation, suggesting that it may represent an adaptive response to elevated replication-associated DSB burden, although the precise mechanism of upregulation remains to be elucidated (43,58). The gene discussed is BRCA2; the disease is cancer.